Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

Congestive Heart Failure Clinical Trial

Official title:

To Define the Role of PDEV in Mediating the Decreased GFR and Attenuated Renal Sodium and cGMP Excretory Response to Acute Saline Volume Expansion in PSD and PDD With Renal Dysfunction.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01544998
• Other study ID #: 11-004257
• Secondary ID: UL1RR0241505P01H
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: January 24, 2012
• Last updated: February 22, 2018
• Start date: February 2012
• Est. completion date: August 2014

Study information

• Verified date: February 2018
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to determine the effects of subcutaneous (under the skin) injection of human B-type natriuretic factor (BNP), Natrecor (nesiritide), a hormone produced by the heart, in combination with Tadalafil on:

• The pumping function of the heart

• Kidney function

• Hormonal function (levels of different hormones in your blood) in persons with lower pumping function of their heart.

Description:

In the American Heart Association/American College of Cardiology classification of heart failure (HF), stage B is defined as patients with abnormal heart structure/function (systolic or diastolic dysfunction) without symptoms. This concept of preclinical HF is based on the fact that abnormal heart structure/function can be detected by complementary methods before the development of symptoms. Patients with those abnormalities may progress to heart failure and are at increased risk of adverse cardiac events. Preclinical systolic dysfunction (PSD) is the initial compensated phase of left ventricular systolic dysfunction without symptoms of HF. We have established that diastolic dysfunction is common in the general population being present in approximately 25% of the population over age 45, the majority of whom are asymptomatic i.e., preclinical diastolic dysfunction (PDD). Cyclic guanosine monophosphate (cGMP) is the second messenger of the natriuretic peptide system (NPS) and the nitric oxide system (NO) and plays an important role in the preservation of myocardial, vascular, and renal function. Hence, disruption of this signal transduction process may contribute to the development of cardiorenal dysfunction. Type V phosphodiesterase (PDEV) metabolizes cGMP and is abundant in the kidney, vasculature, and has been recently reported in the heart. We and others have demonstrated that renal PDEV is up-regulated in experimental HF and may lead to the attenuation of renal cGMP generation in response to both endogenous and exogenous BNP, thus serving as a mechanism for renal resistance to BNP. Furthermore, in experimental overt HF, 10 days of PDEV inhibition treatment resulted in reduction of left ventricular (LV) mass, increased LV fractional shortening and cardiac output but did not improve renal function. However, chronic PDEV inhibition did enhance the renal actions of exogenous BNP, specifically improving glomerular filtration rate (GFR) and renal cGMP generation. PDEV inhibitors are FDA approved for erectile dysfunction and pulmonary hypertension.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: August 2014
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 90 Years

Eligibility

Inclusion Criteria:

Group 1 (PSD)

• an ejection fraction of less than 45% with no clinical signs or symptoms of congestive heart failure;

• a minimal distance on 6-minute walk of >450 meters

• calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the Modification of Diet in Renal Disease (MDRD) formula assessed within the past 24 months. If the creatinine clearance is > 24 months a creatinine test can be drawn at screen/enrollment visit.

• A 6-minute walk distance of 450 meters

Group 2 (PDD)

• ejection fraction of greater than 50% with moderate or severe diastolic dysfunction as assessed by Doppler echocardiography,

• who do not have any signs or symptoms of congestive heart failure

• minimal distance on 6-minute walk of >450 meters

• calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min

Exclusion Criteria:

• Current or anticipated future need for nitrate therapy

• Systolic blood pressure < 90 mmHg or > 180 mm Hg

• Diastolic blood pressure < 40 mmHg or > 100 mmHg

• Resting heart rate (HR) > 100 bpm

• Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum protease inhibitors for HIV).

• Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy or unexplained visual disturbance

• Patients with sickle cell anemia, multiple myeloma, leukemia or penile deformities placing them at risk for priapism (angulation, cavernosal fibrosis or Peyronie's disease)

• Contraindication to nesiritide.

• Patients with an allergy to iodine.

• Valve disease (> moderate aortic or mitral stenosis; > moderate aortic or mitral regurgitation)

• Hypertrophic cardiomyopathy

• Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)

• Pericardial disease

• Have experienced a myocardial infarction or unstable angina, or have undergone percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG at the time of consent

• Severe congenital heart diseases

• Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening

• Second or third degree heart block without a permanent cardiac pacemaker

• Stroke within 3 months of screening or other evidence of significantly compromised central nervous system (CNS) perfusion

• Patients with severe liver disease (AST > 3x normal, alkaline or bilirubin > 2x normal)

• Serum sodium of < 125 milliequivalents (mEq)/dL or > 150 mEq/dL

• Serum potassium of < 3.2 mEq/dL or > 5.7 mEq/dL

• Prior diagnosis of intrinsic renal diseases including renal artery stenosis of > 50%

• Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period

• Less than 21 years of age

• Pregnant or nursing women.

• Women of child bearing potential who do not have a negative pregnancy test at study entry and who are not using effective contraception

Related Conditions & MeSH terms

• Congestive Heart Failure
• Heart Failure

Intervention

Drug:
• Nesiritide
10 ug/kg
• Tadalafil
5 mg
• Placebo
The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
• Saline load
Normal saline 0.9% 0.25 ml/kg/min for 60 minutes

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (3)

Lead Sponsor	Collaborator
Mayo Clinic	National Center for Research Resources (NCRR), National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group	Value at 60 minutes minus value at baseline.	Baseline, 60 minutes after saline load
Primary	Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group	Value at 60 minutes minus value at baseline.	Baseline, 60 minutes after saline load
Secondary	Change in Glomerular Filtration Rate (GFR) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group	Value at 60 minutes minus value at baseline.	Baseline, 60 minutes after saline load
Secondary	Change in Glomerular Filtration Rate (GFR) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group	Value at 60 minutes minus value at baseline.	Baseline, 60 minutes after saline load
Secondary	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group	Value at 60 minutes minus value at baseline.	Baseline, 60 minutes after saline load
Secondary	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group	Value at 60 minutes minus value at baseline.	Baseline, 60 minutes after saline load